Article

Fellow eye study finds efficacy and benefits for photochromic IOL

Results from a study evaluating the first photochromic IOL (Aurium, Medennium) indicate that it provides stable and effective pseudophakic correction and outperforms a yellow IOL under mesopic conditions, said David Mendez Noble, MD, Mexicali, Mexico.

Results from a study evaluating the first photochromic IOL (Aurium, Medennium) indicate that it provides stable and effective pseudophakic correction and outperforms a yellow IOL under mesopic conditions, said David Mendez Noble, MD, Mexicali, Mexico.

The photochromic IOL responds to environmental changes so that it provides blue-blocking protection only as needed. Under conditions in which there is low ultraviolet (UV) light, the optic is clear and does not block blue light, but it changes quickly to yellow in the presence of UV light so that it is able to block the higher levels of blue light that are present in sunlight.

The performance of the photochromic IOL was investigated in a study enrolling 15 patients with the photochromic IOL implanted in one eye and a yellow aspherical IOL (AcrySof IQ [SN60WF], Alcon Laboratories) implanted in the fellow eye. Best-corrected visual acuity (BCVA) was measured indoors at various follow-up visits using Snellen charts with lighting conditions being increased over the range from 11 to 1,200 lux. BCVA also was checked at 30 days postoperatively outdoors, with and without sunglasses worn.

The BCVA results indicated the photochromic IOL was effective and provided vision that was stable through 2 years. In the indoor testing, BCVA increased with both IOLs as the illumination levels increased, but the photochromic IOL outperformed the aspherical IOL in low-level illumination conditions. In the outdoor testing, little difference was found between BCVA measured with and without sunglasses in the photochromic IOL eyes, whereas putting on sunglasses negatively impacted BCVA in 11 eyes with the aspherical IOL.

"Permanently yellow IOLs block 50% of blue light, but there is debate over whether such lenses have a negative impact on night vision, color vision, and the circadian cycle," Dr. Noble said. "The [photochromic IOL] is designed to provide all the benefits of a blue light-blocking IOL without any of the potential downsides."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.